MIT researcher Michael Cima says by combining drug therapy with medical devices, manufacturers can see greater payoffs, according to a Mass Device report.
The drug-device combination becomes a complete therapy, and companies can see returns as early as the end of Phase II trials, Mr. Cima says. Although getting an FDA drug approval can be time-consuming and expensive, Mr. Cima says the payoff is greater. In some cases, medical device manufacturers can incorporate a drug that has already been approved in their device, he says.
Related Articles on Medical Devices:
FDA Extends Comment Period on 510(k) Document
World Sterilization Equipment and Supplies Market to Reach $3.31B by 2017
USC School of Pharmacy Establishes International Center for Regulatory Science
The drug-device combination becomes a complete therapy, and companies can see returns as early as the end of Phase II trials, Mr. Cima says. Although getting an FDA drug approval can be time-consuming and expensive, Mr. Cima says the payoff is greater. In some cases, medical device manufacturers can incorporate a drug that has already been approved in their device, he says.
Related Articles on Medical Devices:
FDA Extends Comment Period on 510(k) Document
World Sterilization Equipment and Supplies Market to Reach $3.31B by 2017
USC School of Pharmacy Establishes International Center for Regulatory Science